drugset / Trial / NCT00740324

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

NCT00740324

Phase 3 Completed 30 enrolled Nihon Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult men. The safety will be evaluated based on adverse events and adverse drug reactions (ADRs) observed with NPO-11 + scopolamine butylbromide or glucagon, and following additional administration of NPO-11. The efficacy will be evaluated based on changes in the frequency of gastric peristalsis classification after the initial dose and the additional dose, and on the presence or absence of gastric peristalsis at each evaluation point.

Timeline

Start
2008-08
Primary completion
2009-03
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 1 mg
Subject Hyoscine butylbromide Unknown 20 mg
Comparator NPO-11 Unknown Other

Indications

No indication recorded.